Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma
Authors:
- Seema GuptaSGSeema Gupta
- Nuzhat HusainNHNuzhat Husain
- Huma KhanHKHuma Khan
- Mps NegiMNMps Negi
- Naseem JamalNJNaseem Jamal
- Ashim GhatakAGAshim Ghatak
- 1 February 2015
- journal article
- clinical trial
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 16 (2) , 346-351
Abstract
This study compared the efficacy and toxicity of Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil (5-FU) in patients of recurrent squamous cell carcinoma of head and neck (SCCHN) treated with palliative intent. Patients with recurrent SCCHN not amenable to curative treatment were randomly assigned to Gefitinib, Methotrexate or Methotrexate plus 5-FU arm. The primary end point was overall survival. Secondary end points of interest were objective response rate, toxicity and quality of life. Total 117 patients were analyzed. Median overall survival and objective response rates were 8.8 months, 7.8 months and 8.1 months and 7.7%, 5.0% and 7.9% in Gefitinib, Methotrexate and Methotrexate plus 5-FU arms respectively with no statistically significant difference between 3 arms. Gefitinib had different toxicity profile compared with other arms. Majority of toxicities were Grade 1 or Grade 2. Gefitinib had significant improvement in quality of life during initial months over Methotrexate. There was no suggestion that Gefitinib significantly prolonged overall survival compared with Methotrexate and Methotrexate plus 5-FU. However, improved Quality of Life with manageable toxicities was observed.Keywords
This publication has 26 references indexed in Scilit:
- Management of Recurrent Head and Neck CancerDrugs, 2011
- Optimal treatment for recurrent/metastatic head and neck cancerAnnals of Oncology, 2010
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2009
- Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2006
- Epidermal Growth Factor Receptor Biology in Head and Neck CancerJournal of Clinical Oncology, 2006
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancerLaboratory Investigation, 2005
- Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experienceAnnals of Oncology, 2004
- Epidermal growth factor receptor and response of head-and-neck carcinoma to therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003